Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
NCT04219475 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2022-04-19
Summary
PROPHETIC GBM - Predicting response patterns to treatment in Glioblastoma (GBM) oncology patients based on host response evaluation during anti-cancer treatments
Conditions
Sponsors & Collaborators
-
OncoHost Ltd.
lead INDUSTRY
Principal Investigators
-
Dror Limon, MD · Sourasky Medical Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-31
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- Israel
Study Locations
More Related Trials
-
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
NCT00897663 ·Status: COMPLETED
-
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
NCT02060890 ·Status: COMPLETED
-
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
NCT00635557 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Procarbazine and Lomustine in Recurrent Glioblastoma
NCT01737346 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
NCT03770468 ·Status: COMPLETED
-
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
NCT03971734 ·Status: TERMINATED ·Phase: PHASE1
-
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
NCT00227032 ·Status: TERMINATED ·Phase: PHASE1
-
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
NCT06855628 ·Status: SUSPENDED ·Phase: PHASE2
-
Navigating the Clinical Research Process for Glioma
NCT05958472 ·Status: NOT_YET_RECRUITING
-
Cilengitide Imaging Trial in Glioblastoma
NCT01558687 ·Status: TERMINATED ·Phase: PHASE1
-
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
NCT01257594 ·Status: COMPLETED ·Phase: PHASE1
-
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients
NCT03758014 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
NCT04121455 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
NCT01269411 ·Status: TERMINATED ·Phase: PHASE1
-
A Study in Recurrent Glioblastoma (GB)
NCT01582269 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
NCT04573192 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety and Imaging Study of GC1008 in Glioma
NCT01472731 ·Status: COMPLETED ·Phase: PHASE2
-
Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients
NCT05728125 ·Status: NOT_YET_RECRUITING
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
NCT00190424 ·Status: COMPLETED ·Phase: PHASE2
-
Precoce Medical Care by the Mobil Support for Patients With Glioblastoma
NCT04516733 ·Status: COMPLETED ·Phase: NA
-
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
NCT01122901 ·Status: TERMINATED ·Phase: PHASE2
-
Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients
NCT01345370 ·Status: COMPLETED
-
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
NCT04019002 ·Status: COMPLETED ·Phase: PHASE1